Literature DB >> 18468935

Evaluation of the anti-tuberculosis activity generated by different multigene DNA vaccine constructs.

Michela Sali1, Sandra Clarizio, Cinzia Pusceddu, Antonella Zumbo, Giovanni Pecorini, Stefano Rocca, Stefania Zanetti, Giovanni Delogu, Giovanni Fadda.   

Abstract

Development of multigenic constructs expressing Mycobacterium tuberculosis (Mtb) antigens may be a strategy to obtain improved DNA vaccines against tuberculosis (TB). Several multigenic constructs expressing two or three Mtb antigens as fusion proteins were developed, both as tPA- and ubiquitin-fusion proteins. To demonstrate proper protein expression and intracellular turnover all multiantigens were tagged with the HA epitope and constructs were used to transfect rhabdomyosarcoma (RD) cells. Antigen expression was demonstrated by immunofluorescence using anti-HA antibodies. C57Bl/6 mice were immunized with selected constructs and protective activity was assessed following aerogenic challenge with Mtb. Several of these constructs induced a significant level of protection in the lung and in the spleen. Immunization with the construct expressing tPA85B-ES6 induced a level of protection that approached that provided by BCG. Immunization with a combination of these constructs induced levels of protection that were not superior to those elicited by a single combination, and immunization with a construct expressing five Mtb antigens could not provide an improved level of protection compared to tPA85B-ES6. We conclude that the activity of a DNA vaccine based on tPA85B-ES6 cannot be enhanced by broadening the antigen repertoire with other highly immunogenic secreted Mtb proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18468935     DOI: 10.1016/j.micinf.2008.02.012

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  6 in total

1.  Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice.

Authors:  Michela Sali; Gabriele Di Sante; Alessandro Cascioferro; Antonella Zumbo; Chiara Nicolò; Valentina Donà; Stefano Rocca; Annabella Procoli; Matteo Morandi; Francesco Ria; Giorgio Palù; Giovanni Fadda; Riccardo Manganelli; Giovanni Delogu
Journal:  Infect Immun       Date:  2010-10-04       Impact factor: 3.441

2.  A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis.

Authors:  Razieh Dalirfardouei; Mohsen Tafaghodi; Zahra Meshkat; Adel Najafi; Aida Gholoobi; Maryam Sadat Nabavinia; Samineh Sajedifar; Mojtaba Meshkat; Ali Badiee; Mohammad Ramezani; Abdol-Reza Varasteh; Mahboubeh Naderinasab
Journal:  Iran J Basic Med Sci       Date:  2020-06       Impact factor: 2.699

3.  Impact of protein domains on PE_PGRS30 polar localization in Mycobacteria.

Authors:  Flavio De Maio; Giuseppe Maulucci; Mariachiara Minerva; Saber Anoosheh; Ivana Palucci; Raffaella Iantomasi; Valentina Palmieri; Serena Camassa; Michela Sali; Maurizio Sanguinetti; Wilbert Bitter; Riccardo Manganelli; Marco De Spirito; Giovanni Delogu
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

4.  Interferon regulatory factor 8-deficiency determines massive neutrophil recruitment but T cell defect in fast growing granulomas during tuberculosis.

Authors:  Stefano Rocca; Giovanna Schiavoni; Michela Sali; Antonio Giovanni Anfossi; Laura Abalsamo; Ivana Palucci; Fabrizio Mattei; Massimo Sanchez; Anna Giagu; Elisabetta Antuofermo; Giovanni Fadda; Filippo Belardelli; Giovanni Delogu; Lucia Gabriele
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

5.  The PPE domain of PPE17 is responsible for its surface localization and can be used to express heterologous proteins on the mycobacterial surface.

Authors:  Valentina Donà; Marcello Ventura; Michela Sali; Alessandro Cascioferro; Roberta Provvedi; Giorgio Palù; Giovanni Delogu; Riccardo Manganelli
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

6.  Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge.

Authors:  Manpreet Kaur; Anant Rai; Rakesh Bhatnagar
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.